Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation study to assess the safety, tolerability and Pharmacokinetics of MGFR1877S.
Solid Tumor
DRUG: MFGR1877S
Incidence of dose dose limiting toxicities (DLTs) by NCI CTCAE, v4.0, Days 1-28 of Cycle 1|Nature of dose limiting toxicities (DLTs) by NCI CTCAE, v4.0, Days 1-28 of Cycle 1
Incidence of adverse events by NCI CTCAE, v4.0, Up to 1 year|Nature of adverse events by NCI CTCAE, v4.0, Up to 1 year|Severity of adverse events by NCI CTCAE, v4.0, Up to 1 year
This is a multicenter, open-label, dose-escalation study to assess the safety, tolerability and Pharmacokinetics of MGFR1877S.